 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 GLOBE NEWSWIRE -- Catalyst Biosciences, Inc. NASDAQ: CBIO today announced a trials in progress poster presentation on Marzeptacog alfa activated or MarzAA, the Companys subcutaneously administered next-generation engineered coagulation Factor VIIa FVIIa, at the upcoming 62nd Annual American Society of Hematology ASH meeting being held virtually December 5-8, 2020. 